NAD+ assay is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-19. Numbers and descriptions here follow the published literature rather than marketing material.
NAD+ also serves as a substrate for enzymes that cleave it, including sirtuins, PARPs, and CD38. These enzymes consume NAD+ and release nicotinamide and ADP-ribose or related products. The dual roles as redox cofactor and signaling substrate connect NAD+ to DNA repair, circadian regulation, and calcium signaling. Cellular NAD+ concentrations vary by tissue, time of day, and stress exposure. How these consumption pathways interact with redox balance remains an active area of research.
NAD+ is a dinucleotide composed of two nucleotides joined by a pyrophosphate linkage. One nucleotide contains adenine, and the other contains nicotinamide. The oxidized form carries a positive charge on the nicotinamide ring and is abbreviated NAD+. It functions as a cofactor in hydride-transfer reactions, accepting electrons in catabolic pathways. In cells, it interconverts with reduced NADH, forming a redox couple central to energy metabolism. The molecule is water-soluble and does not cross cell membranes freely without specific transport or precursor pathways.
The nicotinamide ring undergoes reversible reduction at the para position, converting NAD+ to NADH. This reaction transfers a hydride equivalent, not a free hydrogen atom or electron alone. Because the redox pair has a defined reduction potential, it links oxidation of fuels to respiratory chain activity. Many dehydrogenases use NAD+ as a co-substrate and produce NADH. The ratio of NAD+ to NADH reflects metabolic state and influences flux through several pathways.
Beyond redox chemistry, NAD+ is consumed as a substrate by enzymes that transfer ADP-ribose or remove acetyl groups. Sirtuins use NAD+ in deacylation reactions, poly(ADP-ribose) polymerases use it in DNA damage responses, and CD38 hydrolases convert it to signaling metabolites. Because these enzymes compete for the same pool, changes in NAD+ availability can influence multiple cellular processes. The relative contribution of each consumption route differs by cell type and condition, and precise quantitative links remain an active area of study.
Research on NAD+ spans biochemistry, aging biology, and metabolism. Studies often examine how NAD+ levels change with age, diet, exercise, or disease states, and whether precursor supplementation alters those levels. Findings in animal models do not automatically translate to humans, and measurement methods vary across studies. Questions about tissue-specific effects, long-term consequences, and causal relationships remain open. NAD+ itself is not established as a single therapeutic agent with a broad clinical role.
Nicotinamide adenine dinucleotide, abbreviated NAD+, is a dinucleotide composed of two nucleotides joined by phosphate groups. One nucleotide contains adenine; the other contains nicotinamide. The molecule exists in oxidized (NAD+) and reduced (NADH) forms, and the reversible hydride transfer between them underlies many metabolic oxidation-reduction reactions. In cells, NAD+ serves as an electron acceptor in pathways such as glycolysis, the citric acid cycle, and oxidative phosphorylation. Its concentration and redox ratio vary by compartment, tissue, and metabolic state.
| Property | Value | Notes |
|---|---|---|
| IUPAC name | Nicotinamide adenine dinucleotide | Oxidized dinucleotide form |
| CAS Registry Number | 53-84-9 | Common entry for beta-NAD+ |
| Molecular formula | C21H27N7O14P2 | Free acid form |
| Molar mass | 663.43 g/mol | Calculated for free acid |
| Water solubility | Freely soluble | Charged dinucleotide; less soluble in organic solvents |
Laboratory measurement of NAD+ often begins with rapid quenching of cell or tissue samples to prevent enzymatic conversion. Acidic or alkaline extraction can precipitate proteins, but the chosen method affects recovery of oxidized and reduced forms. Enzymatic cycling assays provide high sensitivity by amplifying a NAD+-dependent reaction. High-performance liquid chromatography and mass spectrometry offer separation and structural confirmation. Each method has trade-offs in throughput, specificity, and the ability to distinguish NAD+ from close analogues.
Purified NAD+ is typically supplied as a white to off-white powder and stored desiccated at low temperature. Airtight containers limit moisture uptake, while protection from light reduces degradation of the nicotinamide ring. Aqueous stock solutions are less stable than solid material and are often aliquoted before freezing. Repeated freeze-thaw cycles can lower integrity, so working portions are kept separate. Purity is commonly checked by ultraviolet absorbance near 260 nm, high-performance liquid chromatography, or mass spectrometry.
Laboratory measurement of NAD+ usually begins with rapid sample quenching because the molecule can change form after collection. Enzymatic cycling assays amplify signal through coupled reactions and are suited to small samples. High-performance liquid chromatography with ultraviolet detection separates NAD+ from related nucleotides. Liquid chromatography-mass spectrometry offers higher specificity and can distinguish NAD+ from close analogs. Each method has trade-offs in sensitivity, throughput, and equipment needs, so reported values depend heavily on extraction and detection choices.
Stability of NAD+ depends on form, temperature, pH, and water content. The solid is generally more stable than solutions, and it should be kept dry and cold. In solution, hydrolysis can cleave the dinucleotide, especially under alkaline conditions or at elevated temperature. Light exposure may also contribute to degradation. Buffers, chelating agents, and sterile handling can reduce losses, but no single condition preserves all preparations indefinitely. Researchers often prepare working solutions shortly before use and verify activity or purity after storage.
Quality control for NAD+ relies on identity, purity, and functional tests. A certificate of analysis may report high-performance liquid chromatography purity, ultraviolet spectrum, water content, and residual solvents. Because NAD+ is hygroscopic, gravimetric values can shift as material absorbs water, so purity should be interpreted alongside storage history. Mass spectrometry confirms molecular identity, while enzymatic assays show whether the material supports dehydrogenase activity. Commercial material is available as the free acid and as salts, and the counterion affects molecular weight, solubility, and how concentrations are calculated.
The stability of NAD+ depends on pH, temperature, light exposure, and the presence of degradative enzymes. Aqueous solutions are generally more stable under mildly acidic to neutral conditions and degrade faster under alkaline conditions or prolonged heat. The solid is hygroscopic and should be stored desiccated, often frozen, and protected from repeated freeze-thaw cycles. In laboratory handling, aliquots reduce repeated temperature changes, and chelating agents may limit metal-catalyzed hydrolysis in some buffers. These practices matter because even small amounts of NADH or hydrolysis products can interfere with quantitative assays.
Quality control for NAD+ materials typically combines identity, purity, and water content checks. Identity may be confirmed by ultraviolet spectrum, retention time in chromatography, or mass accuracy, while purity is assessed by HPLC peak area or quantitative nuclear magnetic resonance. Residual water and solvents can affect molar calculations and enzyme assays, so Karl Fischer titration or thermogravimetric analysis may be used. Commercial materials vary in grade and counterion form, and published methods should specify the exact salt or hydrate when reporting concentrations. Regulatory status depends on intended use, with research reagents, dietary ingredients, and clinical products treated under different frameworks.
Laboratory handling of NAD+ follows standard practices for hygroscopic fine chemicals. Personnel typically avoid inhalation and skin contact, use gloves and eye protection, and work in a ventilated area. Quality control may include ultraviolet absorbance at the nicotinamide maximum, chromatographic purity, water content, and identity confirmation by mass spectrometry. Because commercial preparations can contain counterions, residual solvents, or related nucleotides, a certificate of analysis helps verify the material. Researchers should confirm that the form supplied matches the intended assay.
Measuring NAD+ in biological samples requires care because the molecule is chemically reactive and present at low concentrations in some tissues. Common approaches include enzymatic cycling assays, high-performance liquid chromatography, and liquid chromatography coupled to mass spectrometry. Each method has different sensitivity and specificity, and sample preparation can affect results. Acidic or alkaline extraction steps are used in some protocols, but the choice depends on the analyte and matrix. No single method is universally optimal for every tissue or fluid.
Solid NAD+ is relatively stable when kept dry, cold, and protected from light. Aqueous solutions are more vulnerable to hydrolysis and can lose activity during repeated freeze-thaw cycles or prolonged storage at ambient temperature. Stability depends on pH, ionic strength, and the presence of degrading enzymes or metal ions. For many laboratory uses, aliquots are stored frozen and thawed only once. Exact degradation rates vary by matrix, so stability should be checked for each application rather than assumed.
=== EC 1.6.5 With a quinone or similar compound as acceptor === EC 1.6.5.1: deleted EC 1.6.5.2: NAD(P)H dehydrogenase (quinone) EC 1.6.5.3: now EC 7.1.1.2 NADH:ubiquinone reductase (H+-translocating) EC 1.6.5.4: monodehydroascorbate reductase (NADH) EC 1.6.5.5: NADPH:quinone reductase EC 1.6.5.6: p-benzoquinone reductase (NADPH) EC 1.6.5.7: 2-hydroxy-1,4-benzoquinone reductase EC 1.6.5.8: Now EC 7.2.1.1, NADH:ubiquinone reductase (Na+-transporting) EC 1.6.5.9: NADH:ubiquinone reductase (non-electrogenic) EC 1.6.5.10: NADPH dehydrogenase (quinone) EC 1.6.5.11: Identical to EC 1.6.5.9, NADH:quinone reductase (non-electrogenic) EC 1.6.5.12: demethylphylloquinone reductase
=== Other treatments === Bracing can be used for unstable joints, though it has weak evidence as a pain management strategy. Neuromuscular taping can help prevent injury. TENS units are sometimes used for pain relief. Heat and cold treatment can also help to relieve pain, and have no adverse effects.
A complicating factor is that a single ion channel may have multiple internal "gates" that respond to changes in Vm in opposite ways, or at different rates. For example, although raising Vm opens most gates in the voltage-sensitive sodium channel, it also closes the channel's "inactivation gate", albeit more slowly. Hence, when Vm is raised suddenly, the sodium channels open initially, but then close due to the slower inactivation. The voltages and currents of the action potential in all of its phases were modeled accurately by Alan Lloyd Hodgkin and Andrew Huxley in 1952, for which they were awarded the Nobel Prize in Physiology or Medicine in 1963. However, their model considers only two types of voltage-sensitive ion channels, and makes several assumptions about them, e.g., that their internal gates open and close independently of one another. In reality, there are many types of ion channels, and they do not always open and close independently.
=== Primary === The eRF1 is composed of a polypeptide chain of amino acids in the shape of the letter Y. The protein is composed of 3 major domains: a stem and 2 branches. Each domain has a specific purpose and distinct folding pattern which allows the protein to function properly. While each domain is unique, they all contain the basic structure of an α-β sandwich class, which is essentially a β sheet core surrounded by α helices. Domain 1, sometimes referred to as the N domain, is constructed from a β-sheet core with 4 strands surrounded by 2 α-helices (α2 and α3). The subunits α2 and α3 coil and bind to form a hairpin structure that contains the NIKS motif, YxxCxxxF motif, and the GTS loop. These sites are hypothesized to be the primary appendage in stop codon recognition. Additionally the N-terminus is located in Domain 1, which interacts with Domain 3 in-order to maintain protein stability. Domain 3, sometimes referred to as the C domain, contains the C-terminus of the polypeptide. Additionally, the structure and function of Domain 3, referred to as the M domain, is the least known as optical limitations hinder further research. Domain 2 consists of an α-β sandwich, with one of the outer strands of the sandwich containing no secondary structure. The primary amino acid section allows the GGQ site to form. The folded structure of eRF1 is essentially mimicking the structure of a tRNA molecule. This ensures that the eRF1 machinery fits into the aminoacyl site of the ribosome.
Sources: en.wikipedia.org
Difloxacin (INN), marketed under the trade name Dicural, is a second-generation, synthetic fluoroquinolone antibiotic used in veterinary medicine. It has broad-spectrum, concentration dependent, bactericidal activity; however, its efficacy is not as good as enrofloxacin or pradofloxacin.
Furthermore, denatured samples of the toxin containing α, β, or both subunits have been shown not to induce platelet aggregation or tyrosine phosphorylation suggesting that pellet formation requires the native conformation of the protein. However, reduced convulxin subunits still inhibit the effect of collagen since they bind to a common receptor necessary for collagen activation of platelets. The free toxin might be evacuated through opsonization via the reticuloendothelial system (for the most part the liver and kidneys) or it might degrade through the lysosomes. Therefore, Convulxin acts as an agonist to collagen, inducing platelet activation via GPVI binding, ultimately causing blood clots accumulation in the absence of a homeostatic signal.
The Cantley lab also was one of a few labs that nearly simultaneously identified LKB1 as a regulator of AMPK that also serves to regulate TORC1. For the discovery of PI-3-Kinase and its role in cancer metabolism, Cantley was one of eleven recipients of the inaugural Breakthrough Prize in Life Sciences, "the world's richest academic prize for medicine and biology. The prize, which carries a $3 million cash award, recognizes excellence in research aimed at curing intractable diseases and human life." The fundamental and far-reaching nature of the discovery of PI-3-kinase, together with Cantley's role in mapping the upstream regulation of PI-3-kinase and the downstream signaling pathways, have led to speculation that Cantley is a likely candidate for the Nobel prize in Medicine or Physiology. The growing evidence for a primary role for PI-3-kinase in cancer and its critical role in insulin signaling have served to strengthen the significance of this fundamentally important discovery. The first drug targeting the PI-3-kinase pathway as a treatment for cancer – Idelalisib (PI3K Delta inhibitor) – was approved by the FDA as a treatment for leukemia and two types of lymphoma in July 2014. Other drugs are currently in clinical development.
Sources: en.wikipedia.org
=== Disinfection === Much research has been done in evaluating the ability of the silver ion at inactivating Escherichia coli, a microorganism commonly used as an indicator for fecal contamination and as a surrogate for pathogens in drinking water treatment. Concentrations of silver nitrate evaluated in inactivation experiments range from 10–200 micrograms per liter as Ag+. Silver's antimicrobial activity saw many applications prior to the discovery of modern antibiotics, when it fell into near disuse. Its association with argyria made consumers wary and led them to turn away from it when given an alternative.
As of the 21st century, the vast majority of the world's militaries issue their own field rations, with different varieties of food based on national and cultural considerations. Many use 20th century-style packaging such as cans, boxes, and vacuum-sealed packaging, though some newer rations use retort pouch-based packaging.
Cannabis tea, a cannabis-infused drink prepared by steeping various parts of the cannabis plant in hot or cold water Enviga, a carbonated green tea drink promoted with bogus health claims Jun, a fermented drink made from green tea and honey Kefir, a fermented dairy product Kvass, a traditional fermented drink made from bread List of unproven or disproven cancer treatments Mushroom tea, an infusion of mushrooms in water, made by using edible/medicinal mushrooms (such as lingzhi mushroom) or psychedelic mushrooms (such as Psilocybe cubensis) Tibicos, or "water kefir"
Sources: en.wikipedia.org
NAD+ is the oxidized form, while NADH is the reduced form carrying an added hydride. The two form a redox pair that cells use in many energy-yielding reactions.
NAD+ is a small organic cofactor, not a protein or enzyme. It binds temporarily to enzymes such as dehydrogenases to assist electron transfer.
Intact NAD+ is generally not taken up efficiently by most cells because it is charged and water-soluble. Cells often rely on precursors such as nicotinamide or nicotinamide riboside to produce NAD+ internally.
NAD+ is a coenzyme found in all living cells. It carries electrons in metabolic reactions and also serves as a substrate for enzymes involved in signaling and DNA repair. Its oxidized and reduced forms are central to energy metabolism.